Még nem toboroz
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nianrong Mi (principal investigator)
Még nem toboroz
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nianrong Mi (principal investigator)
Még nem toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nianrong Mi (principal investigator)
Toboroz
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nianrong Mi (principal investigator)
Toboroz
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT07792954· 3. fázis· Pfizer· Forrás
Toboroz
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· 3. fázis· Antengene Biologics Limited· Forrás
Contact: Meili Sun
Még nem toboroz
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple Doses
NCT07841860· 1. fázis· Fujian Shengdi Pharmaceutical Co., Ltd.· Forrás
Contact: Qing Wen
Toboroz
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nianrong Mi (principal investigator)
Toboroz
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245· 2. fázis· Eli Lilly and Company· Forrás
Contact: Xin Wang (principal investigator)
Toboroz
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
NCT07670416· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT07684898· 3. fázis· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Forrás
Toboroz
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
NCT07571161· 3. fázis· Eli Lilly and Company· Forrás
Contact: Hong Bian (principal investigator)
Fut, nem toboroz
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT07663903· 3. fázis· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Forrás
Toboroz
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· 3. fázis· RemeGen Co., Ltd.· Forrás
Contact: Yongfeng Yang
Toboroz
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07327229· 1/2. fázis· Antengene Biologics Limited· Forrás
Contact: Meili Sun
Toboroz
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· 2/3. fázis· Pfizer· Forrás
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nianrong Mi (principal investigator)
Toboroz
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nianrong Mi (principal investigator)
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· 3. fázis· Eli Lilly and Company· Forrás
Contact: Xiaolin Dong (principal investigator)
Toboroz
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· 3. fázis· Pfizer· Forrás
Még nem toboroz
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
NCT07328919· 3. fázis· TransThera Sciences (Nanjing), Inc.· Forrás
Contact: Caixia Sun
Még nem toboroz
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065· First Hospital of China Medical University· Forrás
Contact: Lihua Jin
Toboroz
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· 3. fázis· ArriVent BioPharma, Inc.· Forrás
Contact: Clinical Trials
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nianrong Mi (principal investigator)
Toboroz
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682· 3. fázis· Dizal (Jiangsu) Pharmaceutical Co., Ltd.· Forrás
Contact: Sherry Hu, MD, PhD
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Contact: guohai Su (principal investigator)
Toboroz
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650· 1. fázis· Shanghai Henlius Biotech· Forrás
Contact: Henlius
Meghívásos bevonás
Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen
NCT07514728· Jinan Central Hospital· Forrás
Toboroz
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· 1/2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471· 3. fázis· Eli Lilly and Company· Forrás
Még nem toboroz
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
NCT07116577· 2. fázis· Jinan Central Hospital· Forrás
Contact: Yawen Zhen, Associate Director, Department of Oncology
Toboroz
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113· 1. fázis· Amgen· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· 3. fázis· Amgen· Forrás
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· 3. fázis· Evopoint Biosciences Inc.· Forrás
Contact: Yingjie zhao
Toboroz
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865· 2. fázis· RemeGen Co., Ltd.· Forrás
Contact: Meili sun
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· 3. fázis· Amgen· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257· 2. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· 1/2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435· 3. fázis· Eli Lilly and Company· Forrás
Showing 50 of 96.